Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?

Abstract:

:Progress in methods of investigating endothelial function in humans has led to the demonstration that endothelial dysfunction is an early process involved in the pathophysiology of cardiovascular diseases, and represents a new independent therapeutic target that may help to improve patient health. The administration of antioxidant, anti-hypertensive, lipid lowering or antidiabetic agents appear insufficient to fully restore the normal functions of the vascular endothelium and specific therapeutic strategies are still lacking. In this context, one emerging promising pharmacological approach to prevent endothelial dysfunction is to restore epoxyeicosatrienoic acids (EETs) pathway. EETs are eicosanoids synthesized by endothelial cytochrome epoxygenases that contribute to the regulation of endothelium-dependent dilatation, vascular inflammation, cell proliferation, angiogenesis and hemostasis. Moreover, it has been shown in vivo in humans that EETs act as endothelium-derived hyperpolarizing factors to regulate the vascular tone in both resistance and conduit arteries. In various cardiovascular disorders such as arterial hypertension, a decrease in EETs availability, due to an increased degradation by soluble epoxide hydrolase (sEH), is a deleterious mechanism that contributes to endothelial dysfunction and promotes cardiovascular inflammation and remodeling. Subsequently, the use of sEH inhibitors, which have been shown to decrease blood pressure, limit ischemic injury and prevent hypertrophy in various animal models, appears to be an attractive opportunity to restore endothelial function. Future research will be necessary to demonstrate that sEH inhibitors can prevent endothelial dysfunction in human arteries, which may help to prevent the development of cardiovascular complications and improve cardiovascular prognosis in patients.

journal_name

Pharmacol Ther

authors

Bellien J,Joannides R,Richard V,Thuillez C

doi

10.1016/j.pharmthera.2011.03.015

subject

Has Abstract

pub_date

2011-07-01 00:00:00

pages

1-17

issue

1

eissn

0163-7258

issn

1879-016X

pii

S0163-7258(11)00087-8

journal_volume

131

pub_type

杂志文章,评审
  • Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

    abstract::Initially regarded as "epigenetic modifiers" acting predominantly through chromatin remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase or simply deacetylase inhibitors, have since been recognized to exert multiple cytotoxic actions in cancer cells, often through acetylation of ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2014.04.004

    authors: Bose P,Dai Y,Grant S

    更新日期:2014-09-01 00:00:00

  • The role of flavonoids in autoimmune diseases: Therapeutic updates.

    abstract::Flavonoids are natural polyphenolic compounds which are included in a panoply of drugs and used to treat and/or manage human ailments such as metabolic, cardiovascular, neurological disorders and cancer. Thus, the purpose of this review is to emphasize the importance of flavonoids for the treatment of autoimmune disea...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2018.09.009

    authors: Rengasamy KRR,Khan H,Gowrishankar S,Lagoa RJL,Mahomoodally FM,Khan Z,Suroowan S,Tewari D,Zengin G,Hassan STS,Pandian SK

    更新日期:2019-02-01 00:00:00

  • RNA interference: from gene silencing to gene-specific therapeutics.

    abstract::In the past 4 years, RNA interference (RNAi) has become widely used as an experimental tool to analyse the function of mammalian genes, both in vitro and in vivo. By harnessing an evolutionary conserved endogenous biological pathway, first identified in plants and lower organisms, double-stranded RNA (dsRNA) reagents ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.03.004

    authors: Leung RK,Whittaker PA

    更新日期:2005-08-01 00:00:00

  • PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders.

    abstract::Neurodegenerative diseases represent some of the most devastating neurological disorders, characterized by progressive loss of the structure and function of neurons. Current therapy for neurodegenerative disorders is limited to symptomatic treatment rather than disease modifying interventions, emphasizing the desperat...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107705

    authors: Jamwal S,Blackburn JK,Elsworth JD

    更新日期:2020-10-09 00:00:00

  • Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.

    abstract::Proteolytic degradation of unwanted proteins by the ubiquitin-proteasome system (UPS) is critical for normal maintenance of various cellular functions. Parkinson's disease (PD), one of the most prevalent neurodegenerative disorders, is characterized by prominent and irreversible nigral dopaminergic neuronal loss and i...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2007.04.001

    authors: Sun F,Kanthasamy A,Anantharam V,Kanthasamy AG

    更新日期:2007-06-01 00:00:00

  • Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.

    abstract::Multiple sclerosis (MS) is the commonest cause of progressive neurological disability amongst young, Caucasian adults. MS is considered to be an auto-immune disease that results from an attack against myelin, the layer which surrounds axons. The pathophysiology of MS is complex, with both demyelination and axonal dege...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2010.01.006

    authors: Van der Walt A,Butzkueven H,Kolbe S,Marriott M,Alexandrou E,Gresle M,Egan G,Kilpatrick T

    更新日期:2010-04-01 00:00:00

  • Cocaine use disorder: A look at metabotropic glutamate receptors and glutamate transporters.

    abstract::Glutamate transmission is an important mediator of the development of substance use disorders, particularly with regard to relapse. The present review summarizes the changes in glutamate levels in the reward system (the prefrontal cortex, nucleus accumbens, dorsal striatum, hippocampus, and ventral tegmental area) obs...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107797

    authors: Niedzielska-Andres E,Pomierny-Chamioło L,Andres M,Walczak M,Knackstedt LA,Filip M,Przegaliński E

    更新日期:2021-01-09 00:00:00

  • Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

    abstract::Neutrophils form an essential part of innate immunity against infection. Cancer chemotherapy-induced neutropenia (CCIN) is a condition in which the number of neutrophils in a patient's bloodstream is decreased, leading to increased susceptibility to infection. Granulocyte colony-stimulating factor (GCSF) has been the ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107403

    authors: Abdel-Azim H,Sun W,Wu L

    更新日期:2019-12-01 00:00:00

  • Functional consequences of repeated organophosphate exposure: potential non-cholinergic mechanisms.

    abstract::The class of chemicals known as the "organophosphates" (OPs) comprises many of the most common agricultural and commercial pesticides that are used worldwide as well as the highly toxic chemical warfare agents. The mechanism of the acute toxicity of OPs in both target and non-target organisms is primarily attributed t...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2012.03.001

    authors: Terry AV Jr

    更新日期:2012-06-01 00:00:00

  • Current status of data on cangrelor.

    abstract::P2Y12 receptor inhibition in addition to aspirin is the cornerstone of treatment in patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI). Despite advances in contemporary antithrombotic therapy, periprocedural thrombotic complications such as myocardial infarction ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.01.004

    authors: Qamar A,Bhatt DL

    更新日期:2016-03-01 00:00:00

  • The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis.

    abstract::Decades of research have established that the biological functions of thyrotropin-releasing hormone (TRH) extend far beyond its role as a regulator of the hypothalamic-pituitary-thyroid axis. Gary et al. [Gary, K.A., Sevarino, K.A., Yarbrough, G.G., Prange, A.J. Jr., Winokur, A. (2003). The thyrotropin-releasing hormo...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2008.09.004

    authors: Kamath J,Yarbrough GG,Prange AJ Jr,Winokur A

    更新日期:2009-01-01 00:00:00

  • GABAA receptor pharmacology.

    abstract::gamma-Aminobutyric acid (GABA)A receptors for the inhibitory neurotransmitter GABA are likely to be found on most, if not all, neurons in the brain and spinal cord. They appear to be the most complicated of the superfamily of ligand-gated ion channels in terms of the large number of receptor subtypes and also the vari...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(95)02043-8

    authors: Johnston GA

    更新日期:1996-01-01 00:00:00

  • Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.

    abstract::Pharmacological agents, such as histamine H(2) receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of r...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(03)00015-9

    authors: Aihara T,Nakamura E,Amagase K,Tomita K,Fujishita T,Furutani K,Okabe S

    更新日期:2003-04-01 00:00:00

  • The role of receptor structure in determining adenosine receptor activity.

    abstract::Adenosine produces a wide variety of physiological effects through the activation of cell surface adenosine receptors (ARs). ARs are members of the G-protein-coupled receptor family, and currently, four subtypes, the A1AR, A2AAR, A2BAR, and A3AR, are recognized. This review focuses on the role of receptor structure in...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(99)00051-0

    authors: Olah ME,Stiles GL

    更新日期:2000-02-01 00:00:00

  • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.

    abstract::Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as bio...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107588

    authors: Kurnit KC,Avila M,Hinchcliff EM,Coleman RL,Westin SN

    更新日期:2020-09-01 00:00:00

  • Using animal models to develop therapeutics for Tourette Syndrome.

    abstract::The science of Tourette Syndrome (TS) is advancing at multiple levels of analysis and will be enhanced through the use of animal models. Particular challenges in the development of TS animal models reflect complex features of this disorder, including its waxing and waning course and its "invisible" sensory and psychic...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2005.05.003

    authors: Swerdlow NR,Sutherland AN

    更新日期:2005-12-01 00:00:00

  • Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases.

    abstract::Chitinase 3-like 1 (CHI3L1) is a secreted glycoprotein that mediates inflammation, macrophage polarization, apoptosis, and carcinogenesis. The expression of CHI3L1 is strongly increased by various inflammatory and immunological conditions, including rheumatoid arthritis, multiple sclerosis, Alzheimer's disease, and se...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2019.107394

    authors: Yeo IJ,Lee CK,Han SB,Yun J,Hong JT

    更新日期:2019-11-01 00:00:00

  • GABAB receptors as drug targets to treat gastroesophageal reflux disease.

    abstract::For many years, acid-suppressive therapy has been at the forefront of treating gastroesophageal reflux disease (GERD), yet despite the advent of the proton pump inhibitors (PPIs) some patients continue to experience persistent GERD symptoms. Therapeutic (non-surgical) options for such patients are currently limited. T...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.02.008

    authors: Lehmann A

    更新日期:2009-06-01 00:00:00

  • Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.

    abstract::The gene MUC1 encodes a large membrane-associated glycoprotein, previously termed polymorphic epithelial mucin and now known as MUC1. The majority of the extracellular domain is made up of tandem repeats of 20 amino acids. In some epithelial malignancies, MUC1 is up-regulated, and as a result of changes in glycosyl an...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(99)00003-0

    authors: Miles DW,Taylor-Papadimitriou J

    更新日期:1999-04-01 00:00:00

  • Immunotherapy in sepsis - brake or accelerate?

    abstract::Sepsis, a life threating syndrome characterized by organ failure after infection, is the most common cause of death in hospitalized patients. The treatment of sepsis is generally supportive in nature, involving the administration of intravenous fluids, vasoactive substances and oxygen plus antibiotics to eliminate the...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107476

    authors: Steinhagen F,Schmidt SV,Schewe JC,Peukert K,Klinman DM,Bode C

    更新日期:2020-04-01 00:00:00

  • KRAS-related proteins in pancreatic cancer.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease with a high mortality rate. Genetic and biochemical studies have shown that RAS signaling mediated by KRAS plays a pivotal role in disease initiation, progression and drug resistance. RAS signaling affects several cellular processes in PDAC, includ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2016.09.003

    authors: Mann KM,Ying H,Juan J,Jenkins NA,Copeland NG

    更新日期:2016-12-01 00:00:00

  • Short-term regulation of organic anion transporters.

    abstract::Organic anion transporters (OATs), which belong to the superfamily SLC22A, are key determinants in the absorption, distribution, and excretion of a diverse array of environmental toxins, and clinically important drugs, and, therefore, are critical for the survival of mammalian species. Alteration in the function of th...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2009.08.002

    authors: Duan P,You G

    更新日期:2010-01-01 00:00:00

  • The structure and mechanism of bacterial type I signal peptidases. A novel antibiotic target.

    abstract::Type I signal peptidases are essential membrane-bound serine proteases that function to cleave the amino-terminal signal peptide extension from proteins that are translocated across biological membranes. The bacterial signal peptidases are unique serine proteases that utilize a Ser/Lys catalytic dyad mechanism in plac...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1016/s0163-7258(00)00064-4

    authors: Paetzel M,Dalbey RE,Strynadka NC

    更新日期:2000-07-01 00:00:00

  • The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity.

    abstract::This review focuses on the chemical and enzymatic aspects of the reductive activation of mitomycin C, its disulfide analogs KW-2149 and BMS-181174, and, in less detail, FR66979 and FR900482, newly discovered antitumor antibiotics related to mitomycins. Furthermore, structural aspects of DNA damage induced by these dru...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(97)00088-0

    authors: Tomasz M,Palom Y

    更新日期:1997-10-01 00:00:00

  • LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis.

    abstract::Lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1) was initially identified as the major receptor for oxidized LDL (OxLDL) in endothelial cells. Its inducible expression in macrophages and smooth muscle cell was also observed. LOX-1 is a Type II membrane protein with a typical C-type lectin structur...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(02)00236-x

    authors: Chen M,Masaki T,Sawamura T

    更新日期:2002-07-01 00:00:00

  • Measurement of sister chromatid exchanges and their relationship to DNA damage, repair and cell killing.

    abstract::We have concentrated on how SCE is measured, how it correlates with other measures of cellular damage, and how SCE can be used as a tool to study cell cycle kinetics. We have not discussed the biological significance of SCEs, i.e. why they occur spontaneously, and what role, if any, in cellular preservation they play....

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/0163-7258(89)90030-2

    authors: Deen DF,Morgan WF,Tofilon PJ,Barcellos-Hoff MH

    更新日期:1989-01-01 00:00:00

  • Extracellular vesicles in cancer diagnostics and therapeutics.

    abstract::Cancer promotion, development, and malignant transformation is greatly influenced by cell-to-cell interactions in a complex tissue microenvironment. Cancer and stromal cells secrete soluble factors, as well as deport membrane-encapsulated structures, which actively contribute and mediate cell-to-cell interaction withi...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2021.107806

    authors: Shehzad A,Islam SU,Shahzad R,Khan S,Lee YS

    更新日期:2021-01-16 00:00:00

  • Acquisition of inhibitor-sensitive protein kinases through protein design.

    abstract::Protein phosphorylation is the major post-translational modification used by eukaryotic cells to control cellular signaling. Protein kinases have emerged as attractive drug targets because heightened protein kinase activity has been associated with several proliferative diseases, most notably cancer and restenosis. Un...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0163-7258(98)00060-6

    authors: Bishop AC,Shokat KM

    更新日期:1999-05-01 00:00:00

  • Receptor oligomerization: a pivotal mechanism for regulating chemokine function.

    abstract::Since the first reports on chemokine function, much information has been generated on the implications of these molecules in numerous physiological and pathological processes, as well as on the signaling events activated through their binding to receptors. Despite these extensive studies, no chemokine-related drugs ha...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2011.05.002

    authors: Muñoz LM,Lucas P,Holgado BL,Barroso R,Vega B,Rodríguez-Frade JM,Mellado M

    更新日期:2011-09-01 00:00:00

  • Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency.

    abstract::Glucose-6-phospate dehydrogenase (G6PD) deficiency is estimated to affect more than 400 million people world-wide. This X-linked genetic deficiency puts stress on red blood cells (RBC), which may be further augmented under certain pathophysiological conditions and drug treatments. These conditions can cause hemolytic ...

    journal_title:Pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.pharmthera.2020.107788

    authors: Ryan K,Tekwani BL

    更新日期:2020-12-14 00:00:00